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CC BY-NC-ND license (http://creativeAbstract The attenuated anaerobic bacterium Clostridium novyi-NT (C. novyi-NT) is known
for its ability to precisely germinate in and eradicate treatment-resistant hypoxic tumors in
various experimental animal models and spontaneously occurring canine sarcomas. In this
article, we review the therapeutic and toxicologic aspects of C. novyi-NT therapy, key chal-
lenges and limitations, and promising strategies to optimize its performance via recombinant
DNA technology and immunotherapeutic approaches, to establish C. novyi-NT as an essential
tool in cancer therapy.
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Cancer is a genetic disease arising from a series of somatic
mutations that drive aberrant cellular processes and un-
checked cell division.1,2 As a cancer grows, an ad hoc tumor
vasculature develops. The result is a heterogeneous tumor,(S. Zhou).
ity of Chongqing Medical
to this work.
016.01.003
ng Medical University. Production
commons.org/licenses/by-nc-nd/composed of normoxic, hypoxic, and necrotic regions.
While somatic mutations and alterations in cellular pro-
cesses can be targeted with current systemic therapy,
resistance almost always develops. First, efficacy of sys-
temic therapy is dependent on tumor vasculature. If a
tumor is not well vascularized, as often is the case, sys-
temic therapies do not penetrate all areas of the tumor at
levels that are cytotoxic.3 Second, even if the therapeutic
reaches levels that are pharmacologically active, a rare
pre-existing resistant clone is often present and expands
after treatment.4 The consequence is a rapid resurgence of
a previously conquered foe.5,6and hosting by Elsevier B.V. This is an open access article under the
4.0/).
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gions of hypoxia and necrosis, however, represent an ideal
environment for anaerobic bacteria.7 Specifically, anaerobic
bacteria e or their spores e can be injected systemically or
directly into the tumor and selectively grow in areas of hyp-
oxia, resulting in tumor destruction. Importantly, therapies
based on anaerobic bacteria such as Clostridium spp. can
potentially overcome many of the disadvantages of systemic
therapies and offer a precise way to eradicate tumors that
would otherwise be untreatable.8 In addition, bacterial
therapy harnesses the power of the host immune system. It is
for these reasons that bacterial anticancer therapies are
gaining recognition.History of bacterial anticancer therapy
The concept of using bacteria to treat cancers has a long
history. Over 100 years ago William Coley, a surgeon in New
York, conducted the first systematic assessment of bacte-
rial anticancer therapy.9,10 He intentionally inoculated
cancer patients with cultures of Streptococcus pyogenes,
the causative agent of erysipelas, to induce a local infec-
tion.9 To mitigate the harmful and unpredictable effects of
infection, heat inactivated S. pyogenes, later coupled with
B. prodigiosis, was used to treat a large series of patients.11
Interestingly, Coley observed long-term responses in some
patients, although the efficacy was variable. Since then,
many genera of bacteria have been shown to preferentially
accumulate in tumors to varying degrees of success: Sal-
monella typhimurium, Escherichia coli, Listeria mono-
cytogenes, Clostridium spp., Bifidobacterium spp. and
Mycobacterium bovis.7,12e14
A critical aspect of bacterial anticancer therapy is tumor
localization. Bacterial species that localize specifically to
the tumor environment while demonstrating an inability to
colonize normal tissue are thought to increase targeting
specificity and reduce toxicities associated with
treatment.12e15 As such, obligate and facultative anaer-
obes have been preferentially studied as anticancer agents
to take advantage of the physiological differences between
neoplastic and normal tissues. In particular, Clostridium
spp. (C. butryicum and C. novyi) and Salmonella typhimu-
rium have been extensively studied.
The Clostridia genus consists of a large and heteroge-
neous group of gram-positive, spore-forming bacteria that
exclusively grow in the absence (or at low levels) of oxy-
gen.16 Various subtypes have been tested as anti-cancer
agents including C. butyricum, C. tetani, C. histo-
lyticum,17,18 C. beijerinckii19 and C. acetobutylicum.20 The
first evidence of the ability of Clostridium spp. to colonize
tumors came from studies investigating the intravenous
injection of C. tetani into mice with transplanted and
spontaneous tumors.21 Subsequent work demonstrated that
the non-pathogenic M55 strain of the bacterium C.
butyricum, that was later on reclassified as C. sporogenes
ATCC13732, colonized transplanted tumors in mice and
produced extensive oncolysis after IV injection.22 Inter-
estingly, while non-pathogenic strains of Clostridia were
able to colonize in tumors, oncolysis was less extensive
than that observed with C. butryicum.22,23 After these
initially encouraging results, five patients with locallyadvanced tumors were given 1  1010 C. butyricum spores
(M55 stain) via IV injection.24 Oncolysis was observed in
three patients and one patient showed clinical benefit.
However, no patient with overt signs of spore germination
and oncolysis experienced a complete response. The safety
and efficacy of C. butyricum was assessed further in 49
patients with glioblastomas, the most aggressive primary
brain tumor.25 Each patient received 1  109 spores injec-
ted into the carotid artery. Patients with a minimal clinical
response to the first injection of C. butyricum spores
received a second injection, two weeks after the first.
Germination of C. butyricum spores and development of an
abscess were common, often requiring surgical debride-
ment. Notably, sixteen patients died during treatment and
in those who survived, the rate of recurrence was
unaffected.25
While the preclinical and clinical studies of C. butyricum
spores demonstrated that treatment resulted in reliable
germination confined to neoplastic tissue, complete
destruction of a tumor, including its well-oxygenated re-
gions inhospitable to anaerobic bacteria, was a challenge.
Thus, the next phase of the development of bacterial
therapy based on Clostridium spp. involved methods to
simultaneously kill both well-oxygenated and hypoxic re-
gions of the tumor. These methods have focused on two
approaches to synergistically kill neoplastic cells in well-
oxygenated tumor regions: 1) co-treatment with a cyto-
toxic drug, and 2) genetic modification of Clostridium spp.
Supportive studies investigated the treatment with IV
injected spores of Clostridium spp. and chemotherapeutic
agents in tumor bearing mice and hamsters. These studies
demonstrated an increased oncolysis and responses with
cyclophosphamide and 5-Flurorouracil (5-FU), but not other
agents.26,27 Similarly, several Clostridium spp. have been
genetically engineered to contain cytosine deaminase, an
enzyme from Escherichia coli that converts 5-
fluorocytosine, a non-toxic pro-drug, to 5-FU, a toxic
chemotherapeutic agent.19,28,29 Here, spore germination
and tumor colonization result in an increase in tumor con-
centrations of 5-FU and enhanced anti-tumor responses.29Development of C. novyi-NT as a therapeutic
agent
With the advancement of recombinant DNA technology in
the last few decades, the interest of using bacteria as anti-
cancer agents has re-emerged.7 At the brink of the 21st
century, Vogelstein and colleagues revived the idea of
bacterial anti-cancer therapy and screened a panel of 26
anaerobes for their ability to populate and disseminate
within a human colorectal cancer xenograft model. Clos-
tridium novyi (C. novyi, ATCC #19402) was identified as the
most superior strain and subsequently rendered nonpatho-
genic by eliminating a residential phage carrying a-toxin, a
major toxin responsible for toxicity.15 The resulting clone,
named C. novyi-NT, has been thoroughly investigated since
and is currently undergoing clinical evaluation in a human
Phase I trial for patients with treatment-refractory tumors
(NCT01924689).
C. novyi is ubiquitously encountered in the soil and feces
of the environment from where it can infect animals and
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novyi leading to gas gangrene are often fatal particularly
after traumatic wounds or illicit drug use due to the
secretion of the lethal a-toxin,30 which was deleted in the
therapeutic strain. C. novyi-NT is a highly motile bacterium
that is exquisitely sensitive to oxygen; vegetative forms
cannot survive in oxygen while bacterial spores can only
germinate in hypoxic conditions.31 Fig. 1 shows micrographs
of air-dried C. novyi-NT spores, several of which exhibit a
shell “tail” at the pole (Fig. 1A, B) and vegetative bacteria,
with propeller-like flagella as a means of motility (Fig. 1D).
Once C. novyi-NT spores are exposed to germination con-
ditions, the spores collapse (Fig. 1C, c1e3) and bacteria
outgrow the spores leaving only an empty spore coat behind
(Fig. 1C, e1e3).
A variety of syngeneic and xenograft experimental tu-
mors across multiple animal species have been treated with
intratumoral (IT) or IV administration of C. novyi-NT spores
including colon and pancreatic cancers in mice, aggressive
squamous cell carcinoma in rabbits, and glioblastomas in
rats.15,32e36 Once administered, C. novyi-NT spores germi-
nate locally within tumors and precisely spread throughout
the tumor and its microsatellites, causing hemorrhagic
necrosis, tumor cell lysis and tumor regression.15,32,35,36 As
such, a single IV dose of C. novyi-NT spores into mice and
rabbits bearing tumors is sufficient to induce local tumor
necrosis and an intense inflammatory response, with com-
plete responses seen in 25e30% of the treated animals.32
Notably, these responses were durable and animalsFig. 1 Micrographs of C. novyi-NT spores and outgrowth. (A) At
the spores have a “tail” corresponding to the amorphous shell (arro
the irregular spore surface and a “tail”. (C) Phase-contrast microgra
are spores that are fully intact (i1ei5), collapsed after germinatio
behind (e1ee3). Fig. 1AeC are reprinted from41 with permission f
vegetative C. novyi-NT with numerous flagella. (Bar Z 0.5 mm). R
National Academy of Sciences, U.S.A.developed long-term cellular immunity to the original tu-
mors. In the remaining animals with a partial response to C.
novyi-NT tumors regrew presumably from a well-
vascularized tumor rim that is more resistant to C. novyi-
NT. One problem of the systemic spore administration is the
discrepancy between the need for a large injected spore
dose and the relatively small fraction of spores that are
delivered to tumors,37 thus limiting the efficacy of the
therapy and potentially creating side effects, particularly
in large animals and human patients that have relatively
large blood volumes. By contrast, IT spore administration
can theoretically deliver orders of magnitude more spores
directly into the tumor. Indeed, C. novyi-NT IT adminis-
tration appears to be more effective in delivering a thera-
peutic dose of spores to the tumor, which was most
convincingly shown in the orthotopic F98 rat glioblastoma
model.35,36
Toxicologic evaluation of C. novyi-NT spores in mice
and rabbits found that spores had only minimal clinical
toxicity without an anaerobic space to colonize and were
rapidly cleared from the circulation by the reticuloendo-
thelial system.37 Not surprisingly, C. novyi-NT associated
toxicity was dependent on germination, the spore dose,
route of administration and particularly tumor size, being
most pronounced in animals with larger tumors.37 Clinical
signs of toxicities include lethargy, weight loss and
abscessation as expected with typical bacterial infections
and were predominantly observed in rodents, and to a
lesser degree in rabbits. The treatment-related mortalityomic force micrograph of air-dried C. novyi-NT spores. Some of
w). (B) Magnification of a single C. novyi-NT spore highlighting
ph of spores exposed to germination medium for 24 h. Depicted
n (c1-c3), or fully outgrown only leaving an empty spore coat
rom the Journal of Bacteriology. (D) Electron micrograph of a
eprinted from38 with permission from PNAS, Copyright (2003)
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10e20% in mice.37 Toxicity was manageable in rodents by
administering antibiotics or by ensuring adequate
hydration.36,37
Since cures with C. novyi-NT alone are relatively rare, C.
novyi-NT can be combined with a variety of chemothera-
peutic agents or radiation, a strategy known as Combina-
tion Bacteriolytic Therapy or COBALT.15,33,38,39 It is based
on the rational that C. novyi-NT destroys the hypoxic and
necrotic parts of the tumors, which are traditionally resis-
tant to radiation and cytotoxic agents, while chemother-
apies and radiation attack the tumor cells in the
proliferating, non-hypoxic areas of the tumor (Fig. 2). Both
modalities e chemotherapeutics, particularly microtubule
interacting drugs, and various forms of radiation e resulted
in synergistic responses when combined with C. novyi-NT
with partial or complete regressions in the majority of the
various cancer xenograft models.33,38 However, it should be
noted that in combination with radiation and certain
cytotoxic agents increases in toxicity were observed.Genome of C. novyi-NT and aspects of bio-
engineering
The 2.55-Mb C. novyi-NT genome is smaller in size and
coding capacity than previously sequenced Clostridium
species.40 In contrast to its vegetative form, spores of this
organism are stable in the presence of oxygen. Transmission
electron and atomic force microscopy revealed that C.
novyi-NT spores are surrounded by an amorphous layer
intertwined with honeycomb parasporal layers, which are
sequentially dissolved during the germination process.41
Interestingly, many of the genes encoded by spore mRNA
were not expressed in vegetative cells. Most of these spore-
specific genes encode either spore coat proteins or proteins
with redox activity, which presumably could aidFig. 2 Schematic overview of COBALT. In tumors, blood vesse
development of hypoxic, quiescent tumor areas and well-oxygenate
destroys the hypoxic and necrotic parts of the tumors, which fre
radiation and cytotoxic agents, while well-oxygenated tumor regio
ventional cytotoxic therapies.germination by scavenging reactive oxygen species.40
Spore-specific transcripts were also highly represented in
the transcriptomes of C. novyi-NT treated tumors, sug-
gesting extensive sporulation as a result of the struggle
within a hostile host tumor environment. Expression of the
vegetative C. novyi-NT-specific genes varied dependent on
the growth phase. During the early-log growth phase,
several genes involved in energy metabolism and biosyn-
thesis of cofactors and vitamins were frequently
expressed.40 By contrast, genes responsible for the
biosynthesis, transport of amino acids and other precursor
molecules were upregulated in the mid-log phase, while
only 7 genes predominantly involving metabolic enzymes
were preferentially expressed in late-log phase.40
Furthermore, a group of genes encoding enzymes involved
in fatty acid and lipid metabolism were detected in tran-
scriptomes of infected tumors, which could mirror the
adaptation of C. novyi-NT to the membrane-rich environ-
ment at the infection site.40
Of crucial clinical interest was the identification of
genes that may potentially affect the efficacy and toxicity
associated with C. novyi-NT infections. These included 153
gene products that were predicted to be either cell-surface
associated, secreted or had cytolytic properties, such as
various protein and lipid degrading enzymes (e.g. phos-
pholipase C), toxins (e.g. two hemolysins and two teta-
nolysins), as well as proteins involved in lipid biosynthesis,
cell motility and chemotaxis (e.g. flagellin).40 This knowl-
edge has opened the field for genetic manipulation and bio-
engineering of C. novyi-NT.
Genetic modifications will be necessary to design a C.
novyi-NT strain with the desired therapeutic properties and
toxicological profile. The Clostridia species, however, has
traditionally posed significant challenges because they are
not easily transformable using conventional plasmid vectors
and electroporation techniques. Recently, a technique
utilizing the retrohoming ability of group II intronsls are structurally and functionally abnormal, resulting in the
d, proliferating tumor regions. In COBALT therapy, C. novyi-NT
quently give rise to relapse and are traditionally resistant to
ns largely inaccessible to C. novyi-NT are susceptible to con-
148 V. Staedtke et al.(TargeTron) has been validated in Clostridia, which will
expand the scale of genetic manipulations for this spe-
cies.42,43 Potential genetic manipulations to increase
effectiveness or decrease toxicity include (a) knock-out of
candidate genes that introduce unnecessary toxicity; (b)
knock-in of genes that limit toxicity for example through
expression of proteins that alter the host immune response;
(c) knock-in of genes to increase therapeutic efficacy for
example proteins with cytotoxic activities or enzymes
metabolizing prodrugs; immune-modulators or cytokines to
stimulate the anti-cancer immunity and (d) modifications to
endogenous processes that control bacterial proliferation
within tumors. Though technically feasible, these processes
are very complex and could result in unintended pheno-
types, which might interfere with treatment efficacy. On
the other hand, the development of genetically optimized
strains that are tailored to the patient’s cancer could be
highly rewarding and finally establish bacteria as an
essential treatment tool in cancer.Tumor targeting and destruction by
C. novyi-NT
C. novyi has the ability to target tumors with hypoxia,
which is observed in almost all solid cancers including
glioblastomas (Fig. 3C). Once C. novyi-NT spores meet the
hypoxic tumor region, they germinate and induceFig. 3 Histological sections of rodent glioblastomas during C. n
F98 glioblastoma treated with C. novyi-NT. (B) Gram stained brai
exclusively confined to the tumor (black arrowhead) but not in no
blastoma demonstrating intratumoral distribution of hypoxia, shown
a potent local host-inflammatory response in orthotopic rodent g
surrounded the tumor and restrained the spread of C. novyi-NT
remaining tumor; T, eradicated tumor.substantial tumor regression. Tumor specificity is demon-
strated by the observation that vegetative bacteria cannot
spread into normal tissue owing to higher oxygen levels
(Fig. 3AeB).15,33 While larger tumors are well known to
develop areas of low oxygen tension and necrosis, we have
also found that C. novyi-NT is able to localize to small
islands of tumor cells, suggesting that in fact microscopic
foci of malignant cells could provide sufficient hypoxia to
support bacterial germination.35,36
The mechanisms underlying bacterial tumor destruction
are incompletely understood and may include direct tumor
cell destruction as well as activation of the host immune
system. The genomic and transcriptome analyses of C.
novyi-NT allowed the identification of several highly
expressed genes encoding extracellular proteins, which
could play a key role in this process. Most notable are three
lipid-degrading proteins: phospholipase C (NT01CX0979)
and two lipases (NT01CX2047 and NT01CX0630), all of which
alter the structure of lipid bilayers, change membrane
permeability and thereby create direct cytotoxicity.40
Furthermore, the ability of phospholipases to activate in-
flammatory responses and induce anti-tumor immunity
could have a major effect on the battle between tumor and
bacteria.40
Apart from direct cytoreduction, C. novyi-NT also in-
duces a strong inflammatory response involving pro-
inflammatory cytokines such as IL-6, G-CSF, MIP-2, and
TIMP-1 that recruit a substantial amount of immune cellsovyi-NT treatment. (A) Histological H&E section of syngeneic
n sections revealed that vegetative C. novyieNT bacteria are
rmal brain parenchyma. (C) Pimonidazole staining of F98 glio-
in brown (white arrowhead). (D) C. novyi-NT infection induces
lioblastoma. A ring of leukocytes, stained by anti-CD45 (red),
(green). DAPI is shown in blue. Abbreviations: Br, brain with
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tive anti-tumor immunity.32,36 It is conceivable that
immunogenic cell death (ICD), which is generated by tumor
associated antigen specific T cells that were triggered by
dying tumor cells along with the release of Damage-
Associated Molecular Pattern molecules (DAMPs) by den-
dritic cells,44e46 may play a substantial role in this process.
While exact mechanisms for C. novyi-NT related tumor
destruction are unknown, the observation that vaccination
of BALB/c mice with Clostridium difficile (C. diff.) toxin B
(TcdB)-treated CT26 and B16eF10 melanoma cells resulted
in a long-term tumor specific immune response support this
hypothesis.47 Enhancing this effect could further optimize
the therapeutic efficacy because the anti-tumor immune
response may mediate tumor regression at distant tumor
sites in which C. novyi-NT infection is not established.
Regardless, more studies are needed to further understand
how C. novyi-NT mediates tumor destruction and the role
the immune system plays in this process.Counteracting immunosuppression
Although cancer cells can be detected and destroyed by the
immune system, there is overwhelming evidence that can-
cer cells paralyze the immune responses. Cancer cells are
equipped with an arsenal of escape mechanisms: they can
limit their display of antigens because of restricted pre-
sentations or improper maturation of Antigen-Presenting
Cells (APC), express ligands, e.g. Programmed Death-Ligand
1 (PD-L1), for the receptors that impede the function of
immune cells, secrete immune-suppressive cytokines, e.g.
TGF-b and IL-10, and induce negative regulatory immune
cells such as regulatory T cells (Treg) and Myeloid-Derived
Suppressor Cells (MDSC).48e52
We believe that a strong immune-activating stimulus,
such as a bacterial infection, is able to counteract some of
the tumor-induced immune-suppression mechanisms by
recruitment of immune cells and local production of cyto-
kines and chemokines. Research on oncolytic viruses has
provided support for this hypothesis.53,54 It is very
conceivable that a productive C. novyi-NT infection, just
like an oncolytic virus, can elicit an adaptive anti-tumor
immune response through lysis of tumor cells and release
of tumor-associated antigens into the microenvironment.
As part of this process, two characteristic bacteria-related
signaling pathways, the Pathogen-Associated Molecular
Patterns (PAMPs) and DAMPs, become activated and pro-
mote maturation of APCs, which, along with various cyto-
kines, stimulate antigen-specific CD4þ and CD8þ T cells to
launch an adaptive immune response against cancer cells.
Immune-activating adjuvants including curcumin and cyclic
diguanylate among others could in principle further
enhance this effect.55,56
The ability of C. novyi-NT to modulate the tumor envi-
ronment provides a strong rational for the combination with
other agents that target additional immune-suppressive
mechanisms to optimize the therapeutic success. Various
groups including ours have shown that several therapeutic
agents can reduce tumor-induced immune suppression. For
example, the epigenetic modulator entinostat, anthracy-
cline doxorubicin and anti-metabolites gemcitabine and 5-FU can decrease the number of MDSCs and thus, reverse
the immune-suppression.44,57e60 Furthermore, sunitinib
and vemurafenib, a multi-kinase inhibitor and a BRAF in-
hibitor, respectively, as well as several neutralizing anti-
bodies against GM-CSF receptor, IL-6 receptor, VEGF-A, or
stem cell factor (SCF) have been reported to inhibit MDSC
expansion and mobilization.61e64 Likewise, selective
depletion of Tregs and MDSCs with low-dose cyclophos-
phamide has also been practiced in clinical studies.65
Perhaps the most promising approach is the combination
with T cell checkpoint inhibitors, which have been exten-
sively studied in various cancers. The FDA-approved nivo-
lumab, pembrolizumab and pidilizumab inhibit the
interaction of the Programmed Cell Death 1 (PD-1) receptor
with its ligand PD-L1, whereas ipilimumab targets Cytotoxic
T Lymphocyte Associated Protein 4 (CTLA-4). Several other
checkpoint modulators that target PD-L1 (e.g. avelumab),
Lymphocyte Activation Gene 3 (LAG-3), T Cell Immuno-
globulin and Mucin-3 (TIM-3), IDO or OX40 are currently in
clinical development.48,66e68 These agents could help
reverse immune suppression and prove synergistic with C.
novyi-NT.Comparative studies with C. novyi-NT
The preclinical animal studies demonstrated that the fea-
tures of C. novyi-NT anticancer therapy are attractive to
continue development. First, C. novyi-NT spores were able
to reliably germinate in the hypoxic regions of solid tu-
mors.15 Second, after germination, growth of the vegeta-
tive C. novyi-NT led to profound tumor lysis and long-term
responses in 25%e30% of tumor bearing mice and rabbits
after a single intravenous (IV) dose.32 Third, C. novyi-NT
therapy produces durable resistance in mice to re-
challenge with the same tumor cell line, indicating stimu-
lation of a long-lasting antitumor immune response.32
These qualities led to evaluation of the safety and effi-
cacy of C. novyi-NT in pet dogs with spontaneously occur-
ring tumors. Increasing evidence suggests that
spontaneously occurring tumors in pet dogs more closely
resemble human tumors as they8,69:
1. Are of host origin,
2. Occur in genetically outbred populations,
3. Occur in hosts with intact immune systems,
4. Share similarities in somatically mutated cancer driver
genes,
5. Are of similar size and histological type,
6. Share environmental influences.
To identify the maximum tolerated dose (MTD) of a
single IV injection of C. novyi-NT spores, 6 dogs with
spontaneously occurring solid tumors were treated as part
of a standard phase I dose-escalation study.70 In this study,
two dogs were treated at the initial dose of 3  108 spores
and experienced dose limiting toxicity (DLT), including
abscess formation in a metastatic lymph node in one dog.
Subsequently, the dose was reduced to 3  107 C. novyi-NT
spores. At the reduced dose, 2 of 4 treated dogs experi-
enced DLT, specifically, abscess formation at the site of the
primary tumor of one dog and the spleen of the second dog.
150 V. Staedtke et al.In both cases, C. novyi bacteria were confirmed to be
present by culture and DNA sequencing. The most common
toxicity, experienced by all 6 dogs, was fever. Other com-
mon treatment related toxicities included inappetence and
hematologic and biochemical abnormalities. Importantly,
this study unequivocally demonstrated the ability of C.
novyi-NT spores to germinate in spontaneously occurring
solid tumors and form an abscess after IV injection.
In a second study, 16 dogs with spontaneously occurring
solid tumors received 1  108 C. novyi-NT spores via
intratumoral (IT) injection weekly for a maximum of four
weeks.35 In this study, the authors reasoned that due to the
large blood volume and small tumor sizes seen in pet dogs
compared to mice, previous IV injection of spores in pet
dogs had resulted in too few spores reaching the target
tumor. As such, IT injection was used to deliver an
increased number of spores directly into target tumors.
Treatment was well tolerated and associated with local
infection. Importantly, abscess formation and tumor
destruction were common, with 6 dogs experiencing an
objective response. Of these dogs, 3 had complete re-
sponses and 3 had partial responses.
Based on the safety and efficacy in pet dogs, a Phase I
human trial with IT injected C. novyi-NT spores was initi-
ated. One patient with advanced leimyosarcoma was
treated with 1  104 C. novyi-NT spores injected directly
into a target tumor. The single injection of IT spores in this
patient resulted in tumor necrosis and formation of an
abscess that required surgical debridement.35 As reported
in dogs, toxicities included those associated with local
bacterial infection: an increase in white blood cell count,
fever, and pain.
Regulatory concerns
C. novyi-NT differs from standard drugs in several excep-
tional ways: it is live and vegetative forms self-propagate
within tumor tissues. Therefore, like all live therapeutic
biologics, C. novyi-NT poses unique regulatory and
manufacturing challenges. In the United States, the use of
biologic and recombinant DNA technology is regulated by
two federal agencies: the Food and Drug Administration
(FDA), and the Office of Biotechnology Activities (OBA) at
the National Institutes of Health, which also organizes the
Recombinant DNA Advisory Committee (RAC) and provides
recommendations related to the recombinant DNA tech-
nology used in these agents. For a detailed overview we
would like to refer the reader to an excellent review by
Husain71 and various guidance documents released by the
FDA including “Guidance for Industry: Design and Analysis
of Shedding Studies for Virus or Bacteria-Based Gene
Therapy and Oncolytic Products”72 and “Guidance for In-
dustry: Determining the Need for and Content of Environ-
mental Assessments for Gene Therapies, Vectored
Vaccines, and Related Recombinant Viral or Microbial
Products”.73
Conclusions and future directions
C. novyi-NT holds great promise as a cancer therapeutic but
numerous challenges remain to be solved before thistherapy can obtain regulatory approval and be applied in
clinic. Preclinical and early human experiences have
demonstrated C. novyi-NT’s potential in cancer therapy
and yet, such a therapeutic infection carries a risk for a
significant toxicity, similar to other bacterial infections.
Although the use of the attenuated strain has significantly
decreased treatment related toxicity, additional studies to
understand the mechanism of toxicity and tumor destruc-
tion are necessary to further improve the therapeutic
index. Solving these issues via synthetic biology could
overcome limitations that hamper current cancer therapy
and enables genetic fine-tuning of C. novyi-NT for individ-
ualized cancer therapy. Once perfected, successful C.
novyi-NT therapy could utilize various treatment strategies
dependent on the patient and tumor characteristics: IT
spore delivery may maximize treatment effect in locally
advanced tumors, however, this approach could be insuf-
ficient for metastatic disease, in which case systemic spore
administration might be preferred. Finally, determining the
optimal combination of C. novyi-NT with other cancer
therapies will be critical to maximize treatment success.
One very exciting opportunity is the combination of
bacteriolytic therapy with immunotherapies to augment
the host immune response and trigger a robust antitumor
immunity.
Conflicts of interest
Under a licensing agreement between BioMed Valley Dis-
coveries Inc. and the Johns Hopkins University, S.Z. is
entitled to a share of royalties received by the University on
sales of products described in this article. S.Z is also
Founding Scientific Advisor of Personal Genome Diagnostics
Inc., a company focused on the identification of genetic
alterations in human cancer for diagnostic and therapeutic
purposes. The terms of these arrangements are under
ongoing management by the Johns Hopkins University in
accordance with its conflict of interest policies. The other
authors declare no conflict of interest in the works
described in this article.Acknowledgments
This work was supported by the Francis S. Collins Scholars
Program in Neurofibromatosis Clinical and Translational
Research (V.S.), the Sol Goldman Pancreatic Cancer
Research Center (N.J.R.), NIH/NCI K99-CA190889 (N.J.R.)
and 1R03CA178118-01A1 (R-Y.B.), as well as BioMed Valley
Discoveries Inc. (S.Z.), the Virginia and D.K. Ludwig Fund
for Cancer Research (S.Z.), and NIH/NCI CA062924 (S.Z.).References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next gen-
eration. Cell. 2011;144:646e674.
2. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S,
Diaz Jr LA, Kinzler KW. Cancer genome landscapes. Science.
2013;339:1546e1558.
3. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat
Rev Cancer. 2011;11:393e410.
Clostridium novyi-NT in cancer therapy 1514. Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of
cancer in response to targeted combination therapy. Elife.
2013;2:e00747.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival
with vemurafenib in melanoma with BRAF V600E mutation. N.
Engl J Med. 2011;364:2507e2516.
6. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma
kinase inhibition in non-small-cell lung cancer. N. Engl J Med.
2010;363:1693e1703.
7. Forbes NS. Engineering the perfect (bacterial) cancer therapy.
Nat Rev Cancer. 2010;10:785e794.
8. Fun HK, Hemamalini M, Nithinchandra, Kalluraya B. 4-[(3-
Benzamido-methyl-6-phenyl-6,7-dihydro-5H-1,2,4-triazolo
[3,4-b][1,3,4]thia-d iazin-7-yl)carbon-yl]-3-phenyl-1,2,3-oxadi-
azol-3-ium-5-olate 0.06-hydrate. Acta Crystallogr Sect E Struct
Rep Online. 2010;67:o128e129.
9. Coley WB. The treatment of inoperable sarcoma by bacterial
toxins (the mixed toxins of the Streptococcus erysipelas and
the Bacillus prodigiosus). Proc R Soc Med. 1910;3:1e48.
10. Coley WB. The treatment of malignant tumors by repeated
inoculations of erysipelas. With a report of ten original cases.
Clin Orthop Relat Res. 1893;1991:3e11.
11. Coley WB. The therapeutic value of the mixed toxins of the
streptococcus of erysipelas and Bacillus prodigiosus in the
treatment of inoperable malignant tumors: with a report of
one hundred and sixty cases. Am J Med Sci. 1896;112:251e280.
12. Gravekamp C, Paterson Y. Harnessing Listeria monocytogenes
to target tumors. Cancer Biol Ther. 2010;9:257e265.
13. Hoffman RM, Zhao M. Methods for the development of tumor-
targeting bacteria. Expert Opin Drug Discov. 2014;9:741e750.
14. Minton NP. Clostridia in cancer therapy. Nat Rev Microbiol.
2003;1:237e242.
15. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B.
Combination bacteriolytic therapy for the treatment of
experimental tumors. Proc Natl Acad Sci U. S. A. 2001;98:
15155e15160.
16. Maclennan JD. The histotoxic clostridial infections of man.
Bacteriol Rev. 1962;26:177e276.
17. Connell HC. The study and treatment of cancer by proteolytic
enzymes: preliminary report. Can Med Assoc J. 1935;33:
364e370.
18. Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect
of histolyticus infection and toxin on transplantable mouse
tumors. Proc Soc Exp Biol Med Soc Exp Biol Med. 1947;66:
461e467.
19. Fox ME, Lemmon MJ, Mauchline ML, et al. Anaerobic bacteria
as a delivery system for cancer gene therapy: in vitro activa-
tion of 5-fluorocytosine by genetically engineered clostridia.
Gene Ther. 1996;3:173e178.
20. Theys J, Nuyts S, Landuyt W, et al. Stable Escherichia coli-
Clostridium acetobutylicum shuttle vector for secretion of
murine tumor necrosis factor alpha. Appl Environ Microbiol.
1999;65:4295e4300.
21. Malmgren RA, Flanigan CC. Localization of the vegetative form
of Clostridium tetani in mouse tumors following intravenous
spore administration. Cancer Res. 1955;15:473e478.
22. Moese JR, Moese G. Oncolysis by clostridia. I. Activity of
Clostridium butyricum (M-55) and other nonpathogenic clos-
tridia against the Ehrlich carcinoma. Cancer Res. 1964;24:
212e216.
23. Gericke D, Engelbart K. Oncolysis by clostridia. Ii. Experiments
on a tumor spectrum with a variety of clostridia in combination
with heavy metal. Cancer Res. 1964;24:217e221.
24. Carey RHJ, Whang H, Neter E, Bryant B. Clostridial oncolysis in
man. Eur J Cancer. 1967;3:37e46.
25. Heppner F, Mose JR. The liquefaction (oncolysis) of malignant
gliomas by a non pathogenic clostridium. Acta Neurochir. 1978;
42:123e125.26. Thiele EH, Arison RN, Boxer GE. Oncolysis by clostridia. Iii.
Effects of clostridia and chemotherapeutic agents on rodent
tumors. Cancer Res. 1964;24:222e233.
27. Schlechte H, Schwabe K, Mehnert WH, Schulze B, Brauniger H.
Chemotherapy for tumours using clostridial oncolysis, antibi-
otics and cyclophosphamide: model trial on the UVT 15264
tumour. Arch fur Geschwulstforsch. 1982;52:41e48.
28. Liu SC, Ahn GO, Kioi M, Dorie MJ, Patterson AV, Brown JM.
Optimized clostridium-directed enzyme prodrug therapy im-
proves the antitumor activity of the novel DNA cross-linking
agent PR-104. Cancer Res. 2008;68:7995e8003.
29. Theys J, Landuyt W, Nuyts S, et al. Specific targeting of cyto-
sine deaminase to solid tumors by engineered Clostridium
acetobutylicum. Cancer Gene Ther. 2001;8:294e297.
30. McGuigan CC, Penrice GM, Gruer L, et al. Lethal outbreak of
infection with Clostridium novyi type A and other spore-
forming organisms in Scottish injecting drug users. J Med
Microbiol. 2002;51:971e977.
31. Wells CL, Wilkins TD. Clostridia: sporeforming anaerobic
bacilli. In: Baron S, ed. Medical Microbiology. 4th ed. 1996.
Galveston (TX).
32. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic ther-
apy can generate a potent immune response against experi-
mental tumors. Proc Natl Acad Sci U. S.A. 2004;101:
15172e15177.
33. Dang LH, Bettegowda C, Agrawal N, et al. Targeting vascular
and avascular compartments of tumors with C. novyi-NT and
anti-microtubule agents. Cancer Biol Ther. 2004;3:326e337.
34. Maletzki C, Gock M, Klier U, Klar E, Linnebacher M. Bacterio-
lytic therapy of experimental pancreatic carcinoma. World J
Gastroenterol WJG. 2010;16:3546e3552.
35. Roberts NJ, Zhang L, Janku F, et al. Intratumoral injection of
Clostridium novyi-NT spores induces antitumor responses. Sci
Transl Med. 2014;6:249ra111.
36. Staedtke V, Bai RY, Sun W, et al. Clostridium novyi-NT can
cause regression of orthotopically implanted glioblastomas in
rats. Oncotarget. 2015;6:5536e5546.
37. Diaz Jr LA, Cheong I, Foss CA, et al. Pharmacologic and toxi-
cologic evaluation of C. novyi-NT spores. Toxicol Sci Off J Soc
Toxicol. 2005;88:562e575.
38. Bettegowda C, Dang LH, Abrams R, et al. Overcoming the
hypoxic barrier to radiation therapy with anaerobic bacteria.
Proc Natl Acad Sci U. S. A. 2003;100:15083e15088.
39. Cheong I, Huang X, Bettegowda C, et al. A bacterial protein
enhances the release and efficacy of liposomal cancer drugs.
Science. 2006;314:1308e1311.
40. Bettegowda C, Huang X, Lin J, et al. The genome and tran-
scriptomes of the anti-tumor agent Clostridium novyi-NT. Nat
Biotechnol. 2006;24:1573e1580.
41. Plomp M, McCaffery JM, Cheong I, et al. Spore coat architec-
ture of Clostridium novyi NT spores. J Bacteriol. 2007;189:
6457e6468.
42. Heap JT, Pennington OJ, Cartman ST, et al. The ClosTron: a
universal gene knock-out system for the genus Clostridium. J
Microbiol Methods. 2007;70:452e464.
43. Wang Y, Li X, Milne CB, et al. Development of a gene knockout
system using mobile group II introns (Targetron) and genetic
disruption of acid production pathways in Clostridium beijer-
inckii. Appl Environ Microbiol. 2013;79:5853e5863.
44. Casares N, Pequignot MO, Tesniere A, et al. Caspase-depen-
dent immunogenicity of doxorubicin-induced tumor cell death.
J Exp Med. 2005;202:1691e1701.
45. Michaud M, Martins I, Sukkurwala AQ, et al. Autophagy-
dependent anticancer immune responses induced by chemo-
therapeutic agents in mice. Science. 2011;334:1573e1577.
46. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure
dictates the immunogenicity of cancer cell death. Nat Med.
2007;13:54e61.
152 V. Staedtke et al.47. Huang T, Li S, Li G, et al. Utility of Clostridium difficile toxin B
for inducing anti-tumor immunity. PloS One. 2014;9:e110826.
48. Pardoll DM. The blockade of immune checkpoints in cancer
immunotherapy. Nat Rev Cancer. 2012;12:252e264.
49. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation
and co-inhibition. Nat Rev Immunol. 2013;13:227e242.
50. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of
T-cell activation: potential targets for therapeutic intervention
in cancer, autoimmune disease, and persistent infections.
Immunol Rev. 2009;229:67e87.
51. Lippitz BE. Cytokine patterns in patients with cancer: a sys-
tematic review. Lancet Oncol. 2013;14:e218e228.
52. Nagaraj S, Youn JI, Gabrilovich DI. Reciprocal relationship be-
tween myeloid-derived suppressor cells and T cells. J Immunol.
2013;191:17e23.
53. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new
class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:
642e662.
54. Miyamoto S, Inoue H, Nakamura T, et al. Coxsackievirus B3 is an
oncolytic virus with immunostimulatory properties that is
active against lung adenocarcinoma. Cancer Res. 2012;72:
2609e2621.
55. Gray PM, Forrest G, Wisniewski T, et al. Evidence for cyclic
diguanylate as a vaccine adjuvant with novel immunostimula-
tory activities. Cell Immunol. 2012;278:113e119.
56. Singh M, Ramos I, Asafu-Adjei D, et al. Curcumin improves the
therapeutic efficacy of Listeria(at)-Mage-b vaccine in correla-
tion with improved T-cell responses in blood of a triple-negative
breast cancer model 4T1. Cancer Med. 2013;2:571e582.
57. Kim K, Skora AD, Li Z, et al. Eradication of metastatic mouse
cancers resistant to immune checkpoint blockade by suppres-
sion of myeloid-derived cells. Proc Natl Acad Sci U. S.A. 2014;
111:11774e11779.
58. Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P,
Lee PW. Gemcitabine enhances the efficacy of reovirus-based
oncotherapy through anti-tumour immunological mechanisms.
Br J Cancer. 2014;110:83e93.
59. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD.
Gemcitabine directly inhibits myeloid derived suppressor cells
in BALB/c mice bearing 4T1 mammary carcinoma and aug-
ments expansion of T cells from tumor-bearing mice. Int
Immunopharmacol. 2009;9:900e909.
60. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively
kills tumor-associated myeloid-derived suppressor cellsresulting in enhanced T cell-dependent antitumor immunity.
Cancer Res. 2010;70:3052e3061.
61. Talmadge JE, Gabrilovich DI. History of myeloid-derived sup-
pressor cells. Nat Rev Cancer. 2013;13:739e752.
62. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses
immunosuppression by myeloid derived suppressor cells. Int J
Cancer J Int du Cancer. 2013;133:1653e1663.
63. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of
myeloid-derived suppressor cell accumulation in renal cell
carcinoma patients. Clin Cancer Res Off J Am Assoc Cancer
Res. 2009;15:2148e2157.
64. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance
in advanced malignancy: modulation of myeloid-derived sup-
pressor cell development by blockade of stem-cell factor
function. Blood. 2008;111:219e228.
65. Sevko A, Sade-Feldman M, Kanterman J, et al. Cyclophospha-
mide promotes chronic inflammation-dependent immunosup-
pression and prevents antitumor response in melanoma. J
Investig Dermatol. 2013;133:1610e1619.
66. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory
molecules LAG-3 and PD-1 synergistically regulate T-cell
function to promote tumoral immune escape. Cancer Res.
2012;72:917e927.
67. Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3,
biology and therapeutic applications. Expert Opin Ther Targ.
2011;15:91e101.
68. Anderson AC. Tim-3: an emerging target in the cancer
immunotherapy landscape. Cancer Immunol Res. 2014;2:
393e398.
69. Paoloni M, Khanna C. Translation of new cancer treatments
from pet dogs to humans. Nat Rev Cancer. 2008;8:147e156.
70. Krick EL, Sorenmo KU, Rankin SC, et al. Evaluation of Clos-
tridium novyi-NT spores in dogs with naturally occurring tu-
mors. Am J Vet Res. 2012;73:112e118.
71. Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for
cancer: regulatory considerations for approval. Cancer Gene
Ther. 2015;22:554e563.
72. Guidance for Industry: Design and Analysis of Shedding Studies
for Virus or Bacteria-based Gene Therapy and Oncolytic
Products. 2015.
73. Guidance for Industry: Determining the Need for and Content
of Environmental Assessments for Gene Therapies, Vectored
Vaccines, and Related Recombinant Viral or Microbial Prod-
ucts. 2015.
